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Abstract
Background: Drug markets are very complex and, while many new drugs are registered each year, little is known
about what drives the prescription of these new drugs. This study attempts to lift the veil from this important
subject by analyzing simultaneously the impact of several variables on the prescription of novelty.
Methods: Data provided by four Swiss sickness funds were analyzed. These data included information about more
than 470,000 insured, notably their drug intake. Outcome variable that captured novelty was the age of the drug
prescribed. The overall variance in novelty was partitioned across five levels (substitutable drug market, patient,
physician, region, and prescription) and the influence of several variables measured at each of these levels was
assessed using a non-hierarchical multilevel model estimated by Bayesian Markov Chain Monte Carlo methods.
Results: More than 92% of the variation in novelty was explained at the substitutable drug market-level and at the
prescription-level. Newer drugs were prescribed in markets that were costlier, less concentrated, included more insured,
provided more drugs and included more active substances. Over-the-counter drugs were on average 12.5 years older
while generic drugs were more than 15 years older than non-generics. Regional disparities in terms of age of
prescribed drugs could reach 2.8 years.
Conclusions: Regulation of the demand has low impact, with little variation explained at the patient-level and
physician-level. In contrary, the market structure (e.g. end of patent with generic apparition, concurrence among
producers) had a strong contribution to the variation of drugs ages.
Keywords: Drug market, Drugs prescription, Prescription drivers, Non-hierarchical multilevel model, Bayesian Markov
Chain Monte Carlo methods
Background
New medicines have been associated with increased lon-
gevity on an international scale and, thus, recognized as
a possible vehicle for both medical progress and quality
of life improvement for patients [1]. In Switzerland, a
recent study analyzed the impact of cardiovascular drug
innovation on the longevity of elderly people and it was
found that those “who used newer cardiovascular drugs
in 2003 had longer time till death”, controlling for seve-
ral demographic and health status characteristics [2].
Other authors stated that the substantial number of
innovative pharmaceuticals introduced to the Swiss
market should be examined in regard to the higher costs
they generated [3]. Moreover, significant variations
among cantons’ healthcare costs have been observed [4],
which raises the question of fair access to new products.
Thus, researchers and policy makers are interested in
finding ways to control factors that influence physician’s
adoption of new medications (see, e.g., this paper on
mental disorders drugs [5]).
One additional motivation to focus researches on the
determinants of new drugs prescription is that innovation
and successful diffusion of new drugs are critical for finan-
cial performance of pharmaceutical companies [6]. In
2005 alone, 623 new drugs were registered on the Swiss
Specialities List (a list published by the Federal Office of
Public Health, which contains all the drugs reimbursed by
the basic health insurance [7]), generating a significant
review and administrative work.
For all the aforementioned reasons, we found it im-
portant to deepen the current state of knowledge about
* Correspondence: anne.decollogny@chuv.ch
Institute of Social and Preventive Medicine, Centre Hospitalier Universitaire
Vaudois and Faculty of Biology and Medicine, Route de la Corniche 10, 1010
Lausanne, Switzerland
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Decollogny et al. BMC Health Services Research  (2018) 18:9 
DOI 10.1186/s12913-017-2775-1
the mechanism yielding to new drugs prescription, by
studying what are the main drivers of this novelty in the
Swiss healthcare market.
Drug innovation can take different aspects [8]. A first
distinction should be made between an innovation im-
plying a new substance and one that is a reformulation
of an already existing drug.
In the first category of innovation (i.e. new substance),
one further distinguishes between a structural innovation,
which denotes a drug with a new chemical structure of
the active substance and a pharmacological innovation,
defining a drug that either focuses on a new therapeutic
target, provides a new mechanism of action in the body to
treat the disease, or causes fewer or different undesirable
side effects. This first category of innovations can either
represent clear innovations (first-in-class drugs) or follow-
on drugs (subsequent class entrants) [9], often considered
as possible, yet imperfect, substitutes [10].
As for the second category of innovations (i.e. refor-
mulation), pharmaceutical innovation brings new prop-
erties to a known and already marketed drug, while
pharmacokinetic innovation offers a new and more
appropriate profile for the absorption or elimination of
this product [11]. Novelty in terms of formulation can be
related to the galenic form (pill, coated table, granules,
powder, etc.), the route of administration (oral, topical,
sublingual, inhalation, injection, etc.), the dosage, or the
number of doses. The purposes of such reformulation or
line extension drugs can be manifold: facilitate administra-
tion and the comfort of the patient, adapt the dosage and
facilitate observance of the treatment, and, possibly, di-
minish the impact of market loss at patent expiration by
preventing competition from generics [12].
Note that new drugs might also enter the market
although bringing neither a new substance, nor a new
formulation. This is the case of a generic drug proposed
by a new manufacturer, in a situation of co-marketing,
or under a new brand.
Semantically, one talks about clinical innovation when
this latter brings an added benefit over previous treat-
ments, reduces side effects and, thus, leads to better thera-
peutic benefit, or when it is more adequate for certain
patients’ profiles. However, the frontier between “true”
innovation and comparable new drug is tenuous and in-
cremental innovation, even modest successive modifica-
tions, may finally be considered as innovative [13].
This difficulty of defining true innovation is reflected in
the complexity of disentangling innovative drugs among
the newly registered medicines. Part of the controversy
may arise from how innovation should be assessed [14]
(i.e. looking at the drug’s therapeutic value, its economics
aspects, its patents development, or simply regarding new
drug counts [15]). Given the complexity of drugs
innovation and the absence of consensus as regards ways
to assess it, we tried to facilitate things by capturing the
novelty of a pharmaceutical product using its registration
date in the Swiss Specialities List (i.e. we considered that a
drug was new if it was newly registered on the Swiss
Specialities List, without distinction of any kind).
Regarding the drivers of this innovation, we differenti-
ated between five types of determinants: those related to
physicians, patients, substitutable drug markets, drugs,
and regions (i.e. Swiss cantons), according to previous
knowledge on this subject [6]. For each of these five
categories, several variables were measured.
Physicians were analyzed regarding their clinical area
(specialist or generalists) and their affiliation (hospital or
installed practice). Patients were characterized by their
age, gender, insurance deductible (which might influence
the amount of patients’ co-payment) and a multi-
morbidity index.
Substitutable drug markets are markets in which drugs
are substitutable between each other. Even if there are some
exceptions, for instance to avoid some drugs interactions or
specific side effects for some patients, we considered all
drugs having the same 4th level of Anatomical Therapeutic
Chemical (ATC) [16] code to be substitutable and, thus, the
substitutable markets were simply markets containing
drugs with the same ATC 4th level code. Possible drivers
analyzed for the markets were related to their structure (i.e.
competition aspects [17]), their size [18] (in terms of
treated patients, prescriptions and active structures avail-
able), as well as the expensiveness of their treatments.
Regarding drugs, we differentiated between over-the-
counter and prescription drugs (Rx) and between generic
and non-generic drugs [19]. We also added cantons dum-
mies to capture cultural or marketing variables, which
might influence regional prescription habits in different
cantons, although drugs legislation is defined at the Swiss
federal level [20].
Our analyses were based on Swiss health insurances
data, which included over 2.8 million prescriptions. In a
first time, we partitioned the total variation of the novelty
prescription into five variance components: drug, substi-
tutable market, patient, physician, and region. This
allowed us to identify the largest source of variation and,
therefore, of novelty. Then, we sharpened our analysis by
assessing the amount of variation explained by the
measured drug’s, market’s, patient’s, and physician’s
characteristics, as well as by the cantons’ dummies.
Methods
Studied population
Our source population came from four sickness funds and
consisted in 473,886 insured living in Switzerland in 2006.
Since only drugs delivered by pharmacists are systematically
recorded in Switzerland, the studied population was re-
stricted to cantons prohibiting doctors’ drugs delivery
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(Aarau, Basel-Stadt, Fribourg, Geneva, Jura, Neuchâtel,
Ticino, Valais and Vaud). For each drug, we had knowledge
about its active ingredient (medicinal product), as well as
the information available on its marketed package (i.e. its
brand name, producer, formulation, pharmaceutical form,
dosage, and quantity of doses). All analyzed drugs were
listed on the Swiss Specialties List.
Each observation in our dataset represented a separated
drug prescription, made by a specific physician, for a given
patient (Table 1). If a physician prescribed the same drug
for the same patient, it was considered as only one obser-
vation. A drug with the same active substance but with a
different dosage, formulation, or quantity of doses in the
package represented a new observation. If a different
physician prescribed the same drug, we considered it as a
separate decision and treated it as a new observation. Our
goal was to capture the intention of prescription.
Our analysis did not include any “V” ATC groups (i.e.
diagnostic, medical equipment, contrast product, etc.).
Moreover, the two following selection criteria were
applied at the 4th level ATC:
 more than one specific medicinal product available;
 age difference between the oldest and the newest
drug greater than one.
Variables
The dependent variable was the age of the drug, which we
measured as the difference between the date of its inscrip-
tion on the Swiss Specialities List and 31 December 2006
(analysis time). From an economic point of view, the life
cycle of a product begins with its emergence on the mar-
ket. Thus, the time interval between its registration date
and the time of the analysis represents the age of a drug.
As explained in the background section, this was our proxy
for novelty (i.e. the “younger” the drug, the newer it was
considered).
As will be emphasized in the statistical methods subsec-
tion, the dataset displayed a complex multilevel structure
with five levels, which were both nested and crossed. Ex-
planatory variables were measured at each of these levels.
At the prescription-level, we used two binary variables,
one indicating whether the drug was a prescription drug or
not, the other taking the value one if the drug was a generic.
At the market-level, we used five variables: number of
treated patients (having at least one prescription of a drug
belonging to this market), average treatment cost, number
of drugs, number of active substances (i.e. the number of
ATC 5th level codes), and the Herfindahl-Hirschman index
(HHI) [21]. The number of active substances was defined
as the number ATC 5th level code available in the market.
It has been used as a proxy for the opportunity of real sub-
stitution. As for the HHI, it was computed using the market
shares of the different brands present in this market.
At the patient-level, we had information related to their
age, gender, deductible chosen, and treatment received.
From the information on age, we constructed five indicator
variables representing five age groups (0-19, 20-39, 40-59,
60-79, 80+). Gender was simply included as a dummy indi-
cating whether the patient was a male and the information
on the deductible was also summarized by one indicator
variable for whether the patient had chosen a low deduct-
ible (lower than CHF 400.-). Since 3rd level ATC categories
correspond approximately to different illnesses to treat, we
computed a co-morbidity index defined by the number of
ATC 3rd level categories applying to each patient.
At the physician-level, we used three indicator variables
indicating the physician’s occupation: working in a hos-
pital (but delivering ambulatory care), installed specialist,
and installed generalist (internal medicine and generalists).
Since data were anonymous, we did not have access to
other physicians’ variables (age, rural/urban, etc.).
Finally, at the region-level, we generated nine dummy
variables representing each of the nine cantons.
Statistical methods
The data had a complex multilevel structure, which can
be represented as follows [22]:
Table 1 Example of observations of different prescriptions
Patient Number of boxes
prescribed
Drug Active ingredient Market Physician Canton
Patient A 1 Brand X 10 tablets 500 mg N02BA01 N02BA Dr MD 001 Aarau
Patient A 3 Brand X 10 tablets 500 mg N02BA01 N02BA Dr MD 002 Bern
Patient A 1 Brand X 20 tablets 500 mg N02BA01 N02BA Dr MD 002 Aarau
Patient A 1 Brand X 10 supp 500 mg N02BA01 N02BA Dr MD 002 Bern
Patient A 4 Brand X 10 tablets 500 mg N02BA01 N02BA Dr MD 001 Aarau
Patient A 1 Brand Y 98 tablets 10 mg C09AA02 C09AA Dr MD 001 Aarau
Patient A 2 Brand Y 28 tablets 10 mg C09AA02 C09AA Dr MD 001 Aarau
Patient B 3 Brand Y 98 tablets 10 mg C09AA02 C09AA Dr MD 007 Vaud
Patient B 4 Brand Z 20 tablets 500 mg N02BA01 N02BA Dr MD 008 Vaud
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Figure 1 is self-explanatory and may be simply read as:
prescription i belonging to drug market l and made by
physician k is addressed to patient j in canton m.
The dependent variable (i.e. drug’s age) was treated as
a continuous variable and was log transformed before
analysis as it was extremely skewed. The statistical ana-
lyses were carried out using the MLwiN package from
within Stata [23, 24]. A non-hierarchical multilevel
model with five levels was estimated by Bayesian Markov
chain Monte Carlo (MCMC) methods using a burn-in
period of 5000 iterations followed by a monitoring
period of 10,000 iterations. To ensure a decent pace of
convergence, our statistical analyses were conducted on
a random – hence representative – subsample of
100,000 insured. Independent improper priors were
used for the fixed effects and independent hierarchical
Normal for the random effect. Diffuse Gamma hyper-
priors were specified for precision. The model may be
written in hierarchical notations as follows:
yijklm ¼ β0 þ β
0
1xijklm þ uidj þ uphysk þ umarketl
þucantonm þ εijklm
uidj ¼ βid
0
2 x
id
j þ δidj
uphysk ¼ βphys
0
3 x
phys
k þ δphysk
umarketl ¼ βatc5
0
4 x
market
l þ δmarketl
ucantonm ¼ βcanton
0
5 x
canton
m
εijklm  N 0; σ2obs
 
p βj
 
∝1; j ¼ 0; 1;…; 5
p δidj
σ2id
 
 N 0; σ2id
 
p δphysk
σ2phys
 
 N 0; σ2phys
 
p δmarketl σ
2
market
   N 0; σ2market
 
p 1=σ2id
   Gamma 0:001; 0:001ð Þ
p 1=σ2phys
 
 Gamma 0:001; 0:001ð Þ
p 1=σ2market
   Gamma 0:001; 0:001ð Þ
p 1=σ2obs
   Gamma 0:001; 0:001ð Þ
where:
 xijklm is a vector of variables measured at the
prescription-level (available variables: generic drug
(yes/no), Rx (yes/no))
 xidj is a vector of variables measured at the individual-
level (available variables: age, gender, deductible ≤400
CH Fr (yes/no), co-morbidity index)
 xphysk is a vector of variables measured at the
physician-level (available variables: GP/specialist,
hospital/non-hospital)
 xmarketl is a vector of variables measured at the
market-level (available variables: number of patients
receiving a drug in this market, average yearly
treatment cost, HHI/number of active substances/
number of drugs available, cluster means)
 xcantonm is a vector of variables measured at the
region-level (only dummy variables representing
each canton were used)
canton m1 m2
physician
prescription
patient
market
i1 i2 i3 i5i4 i7i6 i9i8 i10 i11 
j1
…
j3 j5j2 j4 …
k1 k3k2 …
l1 l2
…
…
…
…
Fig. 1 Dataset structure
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An unconditional model was estimated to partition
the overall variance across the five levels, and the
Variance Partition Coefficient (VPC) was computed at
each level to assess the proportion of the response vari-
ance that lies at each specific level of the model
hierarchy [25, 26]. To illustrate the significance of this
variance partitioning based on the empirical Bayes esti-
mates of the random effects, we computed at each level
of the hierarchy the contrasts between the percentiles
P99 and P1, and P75 and P25, in terms of mean drug’s
age difference. For this we used a back-transformation
to compute the predictions on the original scale [27].
Then, we estimated various conditional models and
computed the proportion of explained variation (PEV) at
each level to quantify the contribution of patient’s, phy-
sician’s, market’s, and prescription’s characteristics to the
outcome variance [28]. However, we did not compute
the individual variable PEVs as, unless the regressors are
all orthogonal, the variable-specific PEVs do not add up
to the total level PEV [29]. Instead, to assess the import-
ance of each explanatory variable we computed the con-
trast (i.e. the difference in outcome values) between two
different values of the covariate (e.g. mean drug-age dif-
ference between patients in the older and younger age
classes, mean drug-age difference between a generic and
a non-generic, etc.). Note that the regression coefficients
are interpreted as semi-elasticities and, therefore, allow
us to compute the percentage change in the outcome
value for a unit-change in the regressor value. On the
other hand, the back-transformation approach makes it
possible to calculate the mean difference of the age of
the drugs.
The contrasts were computed by considering all the
available explanatory variables at each level, except at
the market-level, where only one of the three vari-
ables: HHI, number of active substances, and number
of drugs was included at a time, as these variables
were entangled. Therefore, we estimated three differ-
ent regressions, in turn, to compute the impact of
these three variables. We adjusted for confounding by
cluster by including into each regression model the com-
puted cluster means for the variables: age, gender, deduct-
ible, co-morbidity index, generic drug, and Rx [30, 31].
Proper convergence of the MCMC algorithm was
assessed by inspecting the trace plots, smoothed histograms
of the posterior distributions, and auto-correlation func-
tions of the parameters. The goodness of fit of the model
was assessed by inspecting histograms of the random ef-
fects and residuals, as well as scatter plots of residuals ver-
sus predicted mean age of the drug.
All the analyses were carried out using Stata 14.2
(StataCorp LP, 4905 Lakeway Drive, College Station, TX
77845, USA) and MLwiN 2.36 (Centre for Multilevel
Modelling, University of Bristol).
Results
Variables summary
Table 2 describes the different variables used in this
study. Our working subsample contained around
600,000 prescriptions from 328 substitutable markets,
prescribed to 100,000 insured, by 9529 physicians in 9
different cantons. Notice that physicians are identified
by an anonymous provider number, which may
Table 2 Descriptions of the variables used
Variables Share in % (if not
specified differently)
Study Switzerland
Observed prescriptions (599,308 unique values)
Generic drugs 19.30 n.a.a
Rx 78.12 n.a.
Age (mean) 14.59 n.a.
Markets (328 unique values)
Number of treated patients (mean) 7054 n.a.
Yearly treatment cost (mean) 469 n.a.
HHI (mean) 0.56 n.a.
Number of drugs in the market (mean) 18.5 n.a.
Number of active substances
(ATC 5th level) (mean)
2.97 n.a.
Patients (100,000 unique values)
Age = 0-19 19.6 21.7
Age = 20-39 21.6 27.0
Age = 40-59 28.7 35.1
Age = 60-79 23.5 11.6
Age = 80+ 6.7 4.6
Male 43.1 49.0
Deductible >400 34.5 n.a.
Co-morbidity index (ATC 3rd level) (mean) 4.8 n.a.
Physicians (9529 unique values)
General practitioner (prescriptions’ share in %) 33.30 n.a.
Independent specialist (prescriptions’ share in %) 57.63 n.a.
Hospital (prescriptions’ share in %) 9.07 n.a.
Regions (9 unique values)
Aarau (patients’ share in %) 9.79 19.33
Basel-Stadt (patients’ share in %) 4.35 6.30
Fribourg (patients’ share in %) 9.29 8.62
Geneva (patients’ share in %) 24.60 14.62
Jura (patients’ share in %) 0.81 2.35
Neuchâtel (patients’ share in %) 6.86 5.72
Ticino (patients’ share in %) 9.47 10.94
Vaud (patients’ share in %) 25.88 22.21
Valais (patients’ share in %) 8.94 9.90
athese numbers were not available at the time of our study
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correspond to more than one physician (especially for
those working at the hospital).
Women were over-represented in our sample (around
57%), while the young age categories were under-
represented as compared to the Swiss figures. 34% of the
individuals represented in our sample chose a deductible
higher than 400 CHF and, in average, they consumed
drugs from almost 5 different ATC 3rd level codes
(proxy for the number of illnesses).
Independent specialists prescribed more than 55% of the
delivered drugs, while less than 10% of the prescriptions
were written by physicians working in a hospital (drugs pre-
scribed for ambulatory setting, after a hospital discharge or
for 1 day surgery, emergency or planed consultations).
The average age of the drugs prescribed was 14.59 years,
19% of them were generics and 78% were Rx. These drugs
belonged to 328 distinct substitutable markets, which con-
tained around 7000 insured in average. The average HHI
index across these markets was 0.56 while the average
number of active substances was almost 3.
Finally, half of the patients came from two cantons:
Geneva and Vaud, with an under-representation of the
cantons of Aargau, Basel-Stadt and Jura.
Unconditional variance partitioning and contrasts
Results obtained from the partition of the overall vari-
ance across the five levels, as well as the contrasts be-
tween the percentiles P99 and P1, and P75 and P25 of
the empirical Bayes estimates of the random effects are
presented in Table 3. The VPC indicates that most of
the response variance lied at the prescription-level and
at the market-level (VPC of 42.2% and 50.3% respect-
ively). Also, the contrasts display much higher ranges for
these two levels (P99-P1 larger than 50 for both).
As for the three remaining levels, patient’s VPC was
4.9, more than twice as large as that of the physician,
while region’s VPC was only 0.39%. P99-P1 and inter-
quartile range was 13.0 (respectively 2.9) for patient and
11.1 (respectively 1.8) for physician, which also illus-
trates that a larger amount of output’s variation occurred
at the patient level. Finally, note that the contrast be-
tween the canton with the highest average drug’s age
and the one with the lowest was 4.1 years.
Conditional variance partitioning
Table 4 displays the results obtained from the estimation
of the multilevel regression model with the logarithm of
drug’s age as the dependent variable. Since the outcome
was measured on the natural logarithmic scale, the slope
coefficients multiplied by 100 can be interpreted –
ceteris paribus – as the percentage changes in age given
a one unit change in the corresponding covariate [32].
Based on this interpretation, one can conclude that ge-
nerics drug’s age was, on average and ceteris paribus,
87% smaller than that of non-generics. Coefficients asso-
ciated to the Rx variable was negative too, which means
that the average age of drugs requiring a physician’s pre-
scription was lower than that of over-the-counter drugs.
Turning to the variables measured at the market level,
the only variable displaying a positive coefficient – and,
thus, being negatively related to the prescription of nov-
elty – was the Herfindahl-Hirschman index (coefficient
of 0.572). Although negative, the coefficients of the four
other variables measured at this level were quite small,
especially for the number of insured.
In average, older patients took older drugs. Indeed,
compared to the reference category (age = 40-59), the
coefficients associated to older categories were positive
and increasing with age, while the reverse sign was ob-
served for younger individuals (apart from the category
20-39 for which the coefficient is positive but not
significant).
Also, males tended to consume more recent drugs
than females while individuals who chose a higher de-
ductible took – on average – older drugs.
On average and ceteris paribus, independent generalist
prescribed more novelty than independent specialist or
physician hired by a hospital. Finally, there was about
10% variation in drug’s mean age between the two most
extreme cantons (Neuchâtel and Jura).
The contrasts between low and high values of each
covariable on novelty are presented in Table 5 (these
contrasts are interpreted as the difference in average
drug’s age).
The three largest contrasts were, in increasing order
and in absolute value, those resulting from a dimin-
ution of the HHI from 1 to 0.5, from the difference
between a drug requiring a physician’s prescription
and one that did not, as well as from the difference
between a generic and a non-generic (11.55, 12.59
and 15.21 respectively).
It is also interesting to note that the contrast obtained
from a variation of the number of active substances
(5 to 1), the number of drugs (50 to 1), and the
Table 3 Variance partition coefficients (VPC) and contrasts
Level VPC (in %) P99-P1 P75-P25 Max-Min
Prescription 42.3
[39.0; 45.6]
54.3
[51.0; 57.6]
12.4
[11.7; 13.2]
–
Market 50.3
[46.4; 54.2]
52.0
[48.9; 55.1]
16.6
[15.6; 17.6]
–
Patient 4.9
[4.5; 5.3]
13.0
[12.2; 13.7]
2.9
[2.7; 3.1]
–
Physician 2.1
[1.9; 2.3]
11.1
[10.4; 11.8]
1.8
[1.7; 1.9]
–
Region 0.4
[0.3; 0.5]
– – 4.1
[3.8; 4.3]
Confidence intervals in squared brackets
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number of insured (100,000 to 10,000) in each substitut-
able market were approximately of the same magnitude
(between -5.5 and -6.5).
Finally, the impact of the physician’s speciality was
about 1 year, while the contrast between cantons was al-
most 3 years.
Table 6 shows how much of the total variation was ex-
plained by the variables included at the different levels
of our multilevel model.
The variables Rx and generic drug captures 5.5% of
the total VPC at the prescription-level (42.3-34.8). At
the market-level, 11.3% of the total variation was ex-
plained by the variables number of insured, treatment
costs, and HHI (similar results were obtained for the
models using the variables number of drugs or number
of active substances instead of HHI). At the patient-
level, the covariates age, male, deductible and co-
morbidity index explained 2.3% of the total variation,
whereas 1.2% percent was captured by the physician’s
speciality dummies measured at the physician-level.
Table 5 Contrasts between two different values of the covariate
Variable Nature of the contrast Contrast (years)
Prescription level
Rx Yes - No −12.6 [−14.1; −11.1]
Generic drug Yes - No −15.2 [−17.0; −13.4]
Market level
Number of insured 100,000 - 10,000 −5.5 [−6.1; −4.8]
Treatment cost 1000 CHF - 500 CHF −1.8 [−2.0; −1.6]
Herfindahl-Hirschman
index
1 – 0.5 11.6 [10.2; 12.9]
Number of drugs 50 - 1 −6.1 [−6.5; −5.7]
Number of active
substances
5 - 1 −6.5 [−7.2; −5.9]
Patient level
Age (85+) - (0-19) 0.43 [0.38; 0.48]
Male Male - Female −0.16 [−0.18; −0.14]
Deductible (>400 CHF) -
(<=400 CHF)
0.24 [0.21; 0.27]
Co-morbidity index 10 - 1 illnesses −0.024
[−0.027; −0.021]
Physician level
Physician’s specialty Hospital specialist – GP 1.03 [0.91; 1.15]
Region level
Canton Jura - Neuchâtel 2.78 [2.46; 3.10]
Confidence intervals in squared brackets
Table 6 Variance explained by the variables included at the
different level of the model
Prescription Market Patient Physician
Total
VPC (in %)
42.3
[39.0; 45.6]
50.3
[46.4; 54.2]
4.9
[4.5; 5.3]
2.1
[1.9; 2.3]
Residual
variance (in %)
34.8
[34.7 34.9]
38.7
[33.2; 45.3]
2.6
[2.6; 2.7]
1.2
[1.2; 1.3]
Confidence intervals in squared brackets
Table 4 Estimation of the regression coefficients
Variable Coefficient Standard
deviation
P-value 95% credible
interval
Prescription-level
Constant 2.878 0.060 0.000 2.766; 2.989
Rx −0.656 0.004 0.000 −0.663; −0.649
Generic drug −0.870 0.003 0.000 −0.876; −0.865
Market-level
Number of
insured
−2.68e-06 1.05e-06 0.002 −4.92e-06; −6.55e-07
Yearly treatment
cost
−0.0002 0.00003 0.000 −0.000202; −0.000096
HHI 0.572 0.089 0.000 0.418; 0.753
Number of drugs −0.0035 0.0008 0.000 −0.005; −0.002
Number of active
substances
−0.045 0.012 0.000 −0.068; −0.023
Patient-level
Age = 0-19 −0.043 0.004 0.000 −0.050; −0.035
Age = 20-39 0.005 0.003 0.045 −0.001; 0.011
Age = 40-59
(reference)
– – – –
Age = 60-79 0.014 0.003 0.000 0.008; 0.019
Age = 80+ 0.016 0.004 0.000 0.008; 0.024
Male −0.006 0.002 0.002 −0.010; −0.002
Deductible >400
CHF
0.009 0.002 0.000 0.004; 0.014
Co-morbidity
index
−0.0001 0.0003 0.345 −0.0006; 0.0004
Physician-level
General
Practitioner (ref.)
– – – –
Independent
Specialist
0.034 0.004 0.000 0.027; 0.042
Hospital 0.039 0.010 0.000 0.021, 0.057
Region-level
Aarau (reference) – – – –
Basel-Stadt −0.006 0.008 0.251 −0.022; 0.011
Fribourg 0.045 0.008 0.000 0.030; 0.060
Geneva 0.015 0.006 0.010 0.002; 0.027
Jura 0.091 0.016 0.000 0.058; 0.123
Neuchâtel −0.011 0.009 0.089 −0.028; 0.005
Ticino 0.078 0.008 0.000 0.063; 0.093
Vaud 0.021 0.006 0.000 0.008; 0.033
Valais 0.055 0.008 0.000 0.040; 0.070
Confidence intervals in squared brackets
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Discussion
Analyzing the drivers of new drugs prescription is a
complex task, because several players (doctors, patients,
pharmacists, pharmaceutical industries, academic circles,
and regulatory authorities) are likely to influence pre-
scribing habits. The scientific literature describing the
contributions or drawbacks of specific new substances
or formulations is abundant. However, such literature
does not address the issue in a holistic way. Apart from
the fact that the pharmaceutical industry generally favors
innovation for large markets [17] and that patients have
only a minor influence since they often lack scientific ex-
pertise to make choices [16], very little is known about
the determinants of new drugs prescription. To the best
of our knowledge, our study is the first addressing all
the possible determinants simultaneously.
We found that the main drivers of novelty lied at the
market-level and at the prescription-level (more than 92.6%
of the variation in drugs’ age occurred at these two levels).
As for the remaining 7.4%, 4.9% occurred at the physician-
level, 2.1% at the patient-level and 0.4% at the region-level.
More than half of the variation in drugs’ age happened
at the market-level and 11.6% was captured by the co-
variates we included at this level of our multilevel model.
Results indicate that more recent drugs are prescribed in
markets that are costlier, less concentrated, include more
insured, provide more drugs and include more active
substances. For instance, a market containing 100,000
insured prescribed, on average and ceteris paribus, drugs
that were 5.5 years younger than those prescribed in a
market containing 10,000 insured. The variable repre-
senting market concentration (i.e. HHI) had a strong ef-
fect: drugs prescribed were on average 11.5 years older
in markets with a HHI of 1.0 compared to those with a
HHI of 0.5. These observations suggest that producers
tend to develop new products if there is a sufficient
target turn-over and concurrency. The residual variance
of 38.72% that was not due to the covariates we included
was likely related to the age of the pioneers (i.e. first
drug introduced in the market).
The prescription-level explained another great part of
the variance (42.2%), with more novelty in drugs requiring
physicians’ prescription and generics. Over-the-counter
drugs were about 12.5 older, probably because they corres-
pond to reformulations of well-known substances (pioneer
drugs). As for generic drugs, they were registered much
earlier than non-generics (15.2 years in average). This lat-
ter effect was not surprising since generic drugs can only
enter the market after patents’ expiration. The important
thing here is that the effect of all studied variables was ad-
justed for this phenomenon.
At the patient-level, elderly and females tended to con-
sume older drugs, but with a low contrast (i.e. less than
6 months) between the two extremes categories (i.e. 0-
19 and 85+). Our results confirm that most patients
suffered from multiple morbid conditions, especially
among old people [33]. However, we found that the
number of morbid conditions, as measured by our co--
morbidity index, had little impact on the age of pre-
scribed drugs, after partialling out the effect of all other
variables. Deductible did not have a strong impact on re-
ceiving new drugs either. As patients have to pay a
quote-part of only 10%, this did not impact their choice
of consuming newer, and maybe more expensive, drugs.
Therefore, it seems that cost of treatment is not a risk to
create inequities between patients in the Swiss model of
funding.
At the physician-level, generalist tended to prescribe
newly registered drugs more frequently than hospital or
independent specialists did. Although relatively weak (1
year difference), this contrast appears counter-intuitive.
One explanation could be that specialists prescribe drugs
in clinical and therapeutic areas where they have expert-
ise and that these areas have observed fewer market
entries in the early 20’s compared to other areas [6, 34].
Unfortunately, we did not have enough information
about physicians to check this hypothesis. This contrast
can also be related to the prescription of reformulated
drugs by general practitioners (which were considered as
novelty in this study), more convenient for chronic ad-
ministration or for patients with cognitive decline, and
increase patients’ adherence [35].
Finally, at the region-level the contrast in terms of
novelty between two extreme cantons was relatively high
(i.e. almost three-years difference between the Neuchâtel
and Jura). This suggests that regional opinions might be
influenced. Cantonal differences in drugs prescription was
also observed by other authors [36]. We did not found the
amounts spent into marketing efforts to understand if
there were correlated to these regional differences. How-
ever, we noted that Catholic cantons (Ticino, Valais,
Fribourg, Jura), which are typically considered as more
traditional, consumed older drugs. This raises the question
of fair geographic access to new products.
Our study has some limitations, which might be ful-
filled by further researches. First, we did not have access
to detailed information about physicians and, thus, were
not able to test the impact of “contagion through social
networks in new drug uptake” for instance [6]. More-
over, our study was cross-sectional whereas such conta-
gion assumption would require a longitudinal survey to
analyze the geographic dynamic of physicians’ prescrip-
tions habits. We adopted a complex multilevel structure
and adjusted our results to avoid confounding by clus-
ters but decided not to use an over-sophisticated model.
Further researches would be required to deepen the
analysis of the interactions between drugs’ markets and
physicians [37], which might show mixed effects at
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physicians’ level (e.g. simultaneous preferences for some
old medicines and for other recent). It would also be in-
teresting to analyze if the drivers of new drugs prescrip-
tion are homogeneous or different among types of
innovations in each drugs’ markets (new active sub-
stances, new formulations, generics). Further studies
could also address the question of the equity to access to
specific innovations. Finally, it would be interesting to
repeat the analyses within one defined disease area and
range of drugs commonly used (e.g. cardiovascular dis-
ease) and compare the results with those obtained in the
present study.
Conclusion
Producers have two main ways to introduce new drugs:
diversification of dosage and repackaging of already
existing substances or development of new similar sub-
stances. In Switzerland, there are several hundred new
products introduced each year on the healthcare market.
It thus seems important to understand the mechanism
leading to the prescription of these new drugs.
This study provided a global picture regarding the
drivers of new drugs prescription. Our results indicated
that regulation of the demand has low impact, with little
variation explained at the patient-level and physician-
level. In contrary, the market structure (e.g. end of pa-
tent with generic drugs apparition, concurrence among
producers) had a strong contribution to the variation of
prescribed drugs age.
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